HER-2 Positive Breast Cancer Completed Phase 2 / 3 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0042425 (HER-2 Positive Breast Cancer)Completed2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01426880Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast CancerTreatment